A Case of Tuberculous Peritonitis in a Patient with Ankylosing Spondylitis during Infliximab Therapy.
10.3904/kjm.2015.89.5.593
- Author:
Jin Young KANG
1
;
Sung Hwan PARK
;
Seung Ki KWOK
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. seungki73@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Spondylitis, Ankylosing;
Infliximab;
Peritonitis;
Tuberculosis
- MeSH:
Aged;
Biopsy;
Diagnosis;
Humans;
Peritonitis;
Peritonitis, Tuberculous*;
Spondylitis, Ankylosing*;
Tuberculosis;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Medicine
2015;89(5):593-597
- CountryRepublic of Korea
- Language:English
-
Abstract:
Infliximab is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) that is used to treat chronic inflammatory diseases such as ankylosing spondylitis (AS). Side effects include greater susceptibility to severe infections, such as tuberculosis. Positive diagnosis of tuberculous infections, such as tuberculous peritonitis, are often difficult due to the nonspecific nature of symptoms and the rarity of the infection, with definitive diagnoses requiring either a positive culture or histological biopsy. Here, we describe a case of tuberculous peritonitis during infliximab therapy in a 71-year-old man with AS; the disease was confirmed via histopathological examination.
